Patent intelligence · US
US 12194049
Composition for treating carbapenem antibiotic-resistant Acinetobacter baumannii infection
Composition for treating carbapenem antibiotic-resistant Acinetobacter baumannii infection
Patent details — US 12194049
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 14, 2025
- Expiration
- Jan 9, 2045
- Claims
- 13
- CPC classes
- A61K, A61K31/43, A61K31/546, A61P
Quick answer
US 12194049 (Composition for treating carbapenem antibiotic-resistant Acinetobacter baumannii infection) is held by GUANGZHOU CENTURY CLINICAL RESEARCH CO., LTD. Status: granted. Granted Jan 14, 2025. Expires Jan 9, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 13
- CPC classes
- A61K, A61K31/43, A61K31/546, A61P, A61P31/00, A61P31/04
More from GUANGZHOU CENTURY CLINICAL RESEARCH CO., LTD
Related pharmaceutical patents in our USPTO index.
-
US 12274710
Compound for regulating body weight imbalance, composition thereof and application thereof
granted -
US 12269888
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
granted -
US 12084670
Regulating alkaloids
granted -
US 11883432
Chimeric antigen receptor system with adaptable receptor specificity
granted -
US 11865155
Plant extract obtained from Morus plant leaves which has an IC50 value to inhibit a-glucosidase I at a concentration of less than 90 uG/ml, compositions containing same, method of extraction and uses thereof
granted -
US 11667924
Increasing levels of nicotinic alkaloids in plants
granted -
US 11661459
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
granted
Frequently asked questions
What is US patent 12194049?
US 12194049 (Composition for treating carbapenem antibiotic-resistant Acinetobacter baumannii infection) is held by GUANGZHOU CENTURY CLINICAL RESEARCH CO., LTD. Status: granted. Granted Jan 14, 2025. Expires Jan 9, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12194049?
GUANGZHOU CENTURY CLINICAL RESEARCH CO., LTD is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 39 pharmaceutical patents for this assignee.
When does US 12194049 expire?
Our index shows an expiration date of Jan 9, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.